Durability of response in plaque psoriasis patients treated with certolizumab pegol: Two year data from the CIMPASI-1 and CIMPASI-2 phase 3 trials - 22/08/19
Kenneth Gordon, Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI; Kristian Reich, SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany; Andrew Blauvelt, Oregon Medical Research Center, Portland, OR; Diamant Thaçi, University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany; Craig Leonardi, Central Dermatology and Saint Louis University School of Medicine, St Louis, MO; Yves Poulin, Centre de Recherche Dermatologique du Québec Métropolitain, Québec, Canada; Marion Boehnlein, UCB Pharma, Monheim, Germany; Sarah Kavanagh, UCB Pharma, Raleigh, NC; Catherine Arendt, UCB Pharma, Brussels, Belgium; Alice B. Gottlieb, Department of Dermatology, New York Medical College at Metropolitan Hospital, New York, NY
Le texte complet de cet article est disponible en PDF.| Supported by Dermira Inc in collaboration with UCB Pharma. All costs associated with development of this poster were funded by UCB Pharma. |
Vol 81 - N° 4S1
P. AB195 - octobre 2019 Retour au numéro
Article précédent
- Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial
- Dysautonomia for the dermatologist
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?